type 2 diabetes
Conditions
Interventions
A group:Remote management+ incentive 1 + usual care
B group:Remote management+incentive 2+ usual care
C group:usual care
Sponsors
Kunshan First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 at the time of signing the informed consent; 2. Diagnosed with type 2 diabetes mellitus (> 6 months) according to WHO criteria in 1999; 3. Stable treatment of diabetes =2 months, and HbA1c test result of 7.0%=HbA1c=10.5%; 4. Barrier-free use of smart phones, basic Chinese reading and writing ability, simple computing ability; 5. The subjects sign the informed consent voluntarily and agree to strictly follow the requirements of this program.
Exclusion criteria
Exclusion criteria: 1. Chinese patent medicine or Chinese herbal medicine with hypoglycemic effect should be used within 2 months before screening; 2. Receiving chronic (> 2 weeks) systemic glucocorticoid therapy, or having used glucocorticoids within 4 weeks prior to screening (except for topical, intraocular, intranasal, or inhalation administration); 3. Two or more cases of ketosis, diabetic hypertonic state, or lactic acidosis in the 6 months prior to screening; 4. Patients with a history of severe hypoglycemia within 6 months prior to screening, defined as neurohypoglycemia symptoms and requiring treatment to recover, or who were completely unaware of hypoglycemia or had insufficient recognition of hypoglycemia symptoms, and who were considered by the investigator to be unable to communicate and understand hypoglycemia symptoms and appropriate treatment, should also be excluded from the study; 5.2 Type 2 diabetes mellitus with severe chronic complications, such as diabetic foot; 6. History of acute or chronic pancreatitis; 7. The presence of proliferative diabetic retinopathy, or diabetic macular edema, or non-proliferative diabetic retinopathy requiring emergency treatment in the past or at the time of screening; 8. It was diagnosed as autonomic neuropathy, manifested as urinary retention, resting tachycardia, orthostatic hypotension or diabetic diarrhea; 9. Patients with acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, percutaneous coronary intervention (other than diagnostic angiography), TIA, cerebrovascular accident, decompensated heart failure, or NYHA stage III or ? heart failure in the 6 months prior to screening; 10. Acute non-cardiogenic diseases, such as infection, renal failure, hyperthyroidism, etc.; 11. Complicated with other serious cardiovascular diseases: moderate to severe stenosis valvular heart disease, hypertrophic cardiomyopathy or other forms of outflow tract stenosis, acute myocarditis, pericarditis, active endocarditis, suspected or known aneurysm rupture, acute pulmonary embolism or pulmonary infarction; 12. Neurological, muscular, skeletal and rheumatic diseases that may be aggravated by other sports; 13. Mental illness in which the patient is unable to live independently or cooperate with treatment; 14. Breastfeeding, pregnancy or pregnancy planning; 15. Patients deemed unsuitable for study inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The differences in Hba1c results among the three groups were compared; | — |
Secondary
| Measure | Time frame |
|---|---|
| The difference of SMBG detection rate among the three groups was compared;The differences in body weight were compared among the three groups;The differences in diabetes self-efficacy among the three groups were compared; | — |
Countries
China
Contacts
Public ContactZhong Shao
Kunshan First People's Hospital
Outcome results
None listed